Immune Thrombocytopenia epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
(mostly epidemiology complete) |
No edit summary |
||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{Maryam}} | {{CMG}}; {{AE}} {{Maryam}} | ||
==Overview== | ==Overview== | ||
The incidence of Immune thrombocytopenia is approximately 1.6- 3.9 per 100,000 adult individuals worldwide and 1.1- 5.8 per 100,000 individuals among children. Patients of all age groups may develop Immune thrombocytopenia. The Prevalence of chronic Immune thrombocytopenia increases with age. Black and non-hispanic individuals are less likely to develop ITP. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The incidence of Immune thrombocytopenia is approximately 1.6- 3.9 per 100,000 adult individuals worldwide and 1.1- 5.8 per 100,000 individuals among children. The overall incidence rate was higher in women (4.4 per 100,000 person year) than men ( 3.4 per 100,000 person year). | *The incidence of Immune thrombocytopenia is approximately 1.6- 3.9 per 100,000 adult individuals worldwide and 1.1- 5.8 per 100,000 individuals among children. The overall incidence rate was higher in women (4.4 per 100,000 person year) than men ( 3.4 per 100,000 person year).Women are more commonly affected by Immune thrombocytopenia than men. | ||
*In year 2014, the incidence of Immune thrombocytopenia among French people is approximately 2.9/ 100,000 person years with higher incidence among women. The incidence has bimodal distribution with first peak among male children among 1-5 years and men over 75 years of age. However the distribution for women is constant.<ref name="KohliChaturvedi20193">{{cite journal|last1=Kohli|first1=Rahil|last2=Chaturvedi|first2=Shruti|title=Epidemiology and Clinical Manifestations of Immune Thrombocytopenia|journal=Hämostaseologie|volume=39|issue=03|year=2019|pages=238–249|issn=0720-9355|doi=10.1055/s-0039-1683416}}</ref> <ref name="pmidhttps://doi.org/10.1182/blood-2014-05-578336">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=https://doi.org/10.1182/blood-2014-05-578336 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }}</ref> | *In year 2014, the incidence of Immune thrombocytopenia among French people is approximately 2.9/ 100,000 person years with higher incidence among women. The incidence has bimodal distribution with first peak among male children among 1-5 years and men over 75 years of age. However the distribution for women is constant.<ref name="KohliChaturvedi20193">{{cite journal|last1=Kohli|first1=Rahil|last2=Chaturvedi|first2=Shruti|title=Epidemiology and Clinical Manifestations of Immune Thrombocytopenia|journal=Hämostaseologie|volume=39|issue=03|year=2019|pages=238–249|issn=0720-9355|doi=10.1055/s-0039-1683416}}</ref> <ref name="pmidhttps://doi.org/10.1182/blood-2014-05-578336">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=https://doi.org/10.1182/blood-2014-05-578336 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }}</ref> | ||
| Line 33: | Line 34: | ||
*There is no racial predilection to [disease name]. | *There is no racial predilection to [disease name]. | ||
* | *Black and non-hispanic individuals are less likely to develop ITP, thereafter, the providers should suspect alternative diagnosis or secondary ITP in these races.<ref name="KimGrimes2020">{{cite journal|last1=Kim|first1=Taylor Olmsted|last2=Grimes|first2=Amanda B.|last3=Kirk|first3=Susan E.|last4=Gilbert|first4=Megan M.|last5=Reed|first5=Helen D.|last6=Staggers|first6=Kristen A.|last7=Walker|first7=Lauryn A.|last8=Arulselvan|first8=Abinaya|last9=Cohen|first9=A. Sarah|last10=Lambert|first10=Michele P.|last11=Despotovic|first11=Jenny M.|title=Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences|journal=Blood|volume=136|issue=5|year=2020|pages=640–643|issn=0006-4971|doi=10.1182/blood.2020004888}}</ref> | ||
===Gender=== | ===Gender=== | ||
Latest revision as of 17:55, 8 February 2021
|
Immune Thrombocytopenia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Immune Thrombocytopenia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Immune Thrombocytopenia epidemiology and demographics |
|
FDA on Immune Thrombocytopenia epidemiology and demographics |
|
CDC on Immune Thrombocytopenia epidemiology and demographics |
|
Immune Thrombocytopenia epidemiology and demographics in the news |
|
Blogs on Immune Thrombocytopenia epidemiology and demographics |
|
Risk calculators and risk factors for Immune Thrombocytopenia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Barkhordarian, M.D.[2]
Overview
The incidence of Immune thrombocytopenia is approximately 1.6- 3.9 per 100,000 adult individuals worldwide and 1.1- 5.8 per 100,000 individuals among children. Patients of all age groups may develop Immune thrombocytopenia. The Prevalence of chronic Immune thrombocytopenia increases with age. Black and non-hispanic individuals are less likely to develop ITP.
Epidemiology and Demographics
Incidence
- The incidence of Immune thrombocytopenia is approximately 1.6- 3.9 per 100,000 adult individuals worldwide and 1.1- 5.8 per 100,000 individuals among children. The overall incidence rate was higher in women (4.4 per 100,000 person year) than men ( 3.4 per 100,000 person year).Women are more commonly affected by Immune thrombocytopenia than men.
- In year 2014, the incidence of Immune thrombocytopenia among French people is approximately 2.9/ 100,000 person years with higher incidence among women. The incidence has bimodal distribution with first peak among male children among 1-5 years and men over 75 years of age. However the distribution for women is constant.[1] [2]
Prevalence
- The prevalence of chronic immune thrombocytopenia ( lasting longer than 12 months) is approximately 9.5-11.2 per 100,000 individuals in the United States.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop Immune thrombocytopenia.
- The Prevalence of chronic Immune thrombocytopenia increases with age; the childhood ITP remits spontaneously.
- Immune thrombocytopenia commonly affects individuals younger than 5 years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- Black and non-hispanic individuals are less likely to develop ITP, thereafter, the providers should suspect alternative diagnosis or secondary ITP in these races.[3]
Gender
- [Disease name] affects men and women equally.
- Women are more commonly affected by Immune thrombocytopenia than men.
Season
- The majority of Immune thrombocytopenia cases are reported in January and the minority in summer in all age group probably due to viral infection..[1] [2]
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ 1.0 1.1 Kohli, Rahil; Chaturvedi, Shruti (2019). "Epidemiology and Clinical Manifestations of Immune Thrombocytopenia". Hämostaseologie. 39 (03): 238–249. doi:10.1055/s-0039-1683416. ISSN 0720-9355.
- ↑ 2.0 2.1 Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes" Check
|url=value (help). Biochem Pharmacol. 24 (17): 1639–41. PMID https://doi.org/10.1182/blood-2014-05-578336 Check|pmid=value (help). - ↑ Kim, Taylor Olmsted; Grimes, Amanda B.; Kirk, Susan E.; Gilbert, Megan M.; Reed, Helen D.; Staggers, Kristen A.; Walker, Lauryn A.; Arulselvan, Abinaya; Cohen, A. Sarah; Lambert, Michele P.; Despotovic, Jenny M. (2020). "Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences". Blood. 136 (5): 640–643. doi:10.1182/blood.2020004888. ISSN 0006-4971.